explore -WSS

explore

author：Wikipedia 2025-09-27 22:45:57 - browse：6

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Alnylam reports growth in sales of rare disease treatments

WSS

Biden report: The neurospychology of memory and aging

Pharma showers House GOP doctor with campaign cash

To avoid data mishandling cases, universities eye AI and other tools

Vaccine advisory panel ACIP left half staffed by HHS

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

knowledge

explore

focus

Psychedelics group wrestles with new pharma identity

'Revelatory' study finds a smoking impact that remains after quitting

DIEP, the 'gold standard' of breast reconstruction, is under threat

2 officers injured in shooting in Orlando, police say

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A controversial new treatment promises to make little people taller

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biden report: The neurospychology of memory and aging

The cancer drug shortage isn’t new — and neither are the solutions

Physicians aren't 'burning out.' They're suffering from moral injury

entertainment

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

The a glaring gap in research on serious mental illness and primary care

Senators start work on Medicare physician payment reform

Medicare threatens to cut off funding for HCA's Mission hospital

Readout LOUD podcast: How biotech is using artificial intelligence

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

hotspot

focus

knowledge

knowledge